newsThe recommendation of Adcetris (brentuximab vedotin) represents the first new…
13 July 2020 | By Hannah Balfour (European Pharmaceutical Review)
The recommendation of Adcetris (brentuximab vedotin) represents the first new frontline therapy for systemic anaplastic large cell lymphoma (sALCL) in several decades.